“Thin” Molecules for Treating Obesity and Type II Diabetes

Description:

Project ID: D2016-29

IP Status: Provisional patent application #62/301,134

Invention Description and Novelty: “Thin” molecules offer stronger binding to PPAR and include greater lipid burning and glucose lowering properties.

Applications: Dyslipidemia, obesity and type II diabetes

 

 Value propositions:

•       Bilirubin reduces body fat percentage and glucose levels, but not in PPARα knockout mice.

•       Thin molecules bind to PPARto decrease fat mass,

which results in the prevention of type II diabetes.

•       In a humanized mouse model of hyperbilirubinemia, which typically have a moderate increase in plasma bilirubin levels (50%-1.5 fold elevations), we have observed reduced fat mass, increased lean mass, and lower plasma insulin and glucose levels when treated with Thin molecules.

•       Compounds and methods described can be embodied in the form of a kit or kits.

•       Next steps: Treat adipocytes during an adipogenesis assay to show the effect of Thin Molecules on lipid accumulation. Then, treat mouse models of obesity and diabetes to show that the Thin Molecules can reduce fat mass and blood glucose levels.

•       Compounds will provide competition for fibrate drug class that are ligands for PPAR, including Fenofibrate, Bexafibrate, Ciprofibrate, Clofibrate, Gemfibrozil, Clinofibrate.

 

Patent Information:
For Information, Contact:
Anne Izzi
Licensing Associate
The University of Toledo
419 530 6226
anne.izzi@utoledo.edu
Inventors:
Terry Hinds
Christopher Trabbic
David Stec
Keywords:
Adipogenesis
Bilirubin
Biliverdin
Biliverdin Reductase
Fenofibrate
FGF21
Heme Oxygenase
Lipid Accumulation
PPAR
PPARa
WY 14,643